Daxor corporation announces 61% increase in q1 2021 sales revenue and further acquisitions of its bva-100® blood volume analyzer by leading medical centers throughout the u.s.

New york, ny, may 13, 2021 (globe newswire) -- daxor corporation (nyse mkt: dxr), the global leader in blood volume measurement technology, today announced a q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. in addition, the sales team has recorded the opening of five new customer accounts utilizing bva and reports a growing pipeline of additional acquisitions of daxor's bva-100 blood volume analyzer slated for q3 2021 at major medical centers across the u.s.
DXR Ratings Summary
DXR Quant Ranking